AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
AngioDynamics, Inc. (ANGIO) filed this Current Report on Form 8-K on May 28, 2025. The filing details the entry into a new material definitive agreement regarding a secured revolving credit facility. The Company is a Delaware corporation with principal executive offices in Latham, New York.
Key Financial Metrics and Debt Structure
The filing establishes a new $25 million secured revolving credit facility with JPMorgan Chase Bank, N.A. Key terms include:
- Facility Size: $25 million Revolving Facility.
- Maturity Date: May 28, 2027.
- Availability Block Period: Until the Company demonstrates a fixed charge coverage ratio greater than 1.00 to 1.00, the facility is reduced by $5 million.
- Letters of Credit Cap: Limited to $2 million at closing.
- Interest Rates: Adjusted Term SOFR + 2.00% or Alternate Base Rate (ABR) + 1.00%.
- Commitment Fee: 0.20% per annum on the unused portion.
- Collateral: Secured by first priority security interests in substantially all assets of the Loan Parties and Guarantors.
The filing states the Company is "well capitalized with existing cash on hand" but entered the agreement to manage working capital fluctuations during a manufacturing transfer process. The filing text does not provide specific values for current revenue, profit, cash flow, or existing debt levels.
Material Changes and Covenants
The primary material change is the execution of the Credit Agreement on May 28, 2025. The agreement includes a financial covenant requiring the Company to maintain a fixed charge coverage ratio of not less than 1.05 to 1.00 as of the end of each calendar month, commencing after the end of the Availability Block Period.
Management Commentary and Outlook
Management views the new credit facility as a reflection of good financial management. The proceeds are designated for working capital and general corporate needs. The facility is intended to provide incremental flexibility to manage potential working capital fluctuations associated with the Company's manufacturing transfer process without impacting its strategic growth trajectory. No specific forward-looking financial guidance or revenue projections were included in this filing.
Investor Verification Checklist
- Verify the current status of the "Availability Block Period" and whether the $5 million reduction in facility availability remains in effect.
- Review the Company's most recent quarterly or annual report to confirm the "well capitalized" status and existing cash on hand levels.
- Monitor the Company's ability to meet the 1.05 to 1.00 fixed charge coverage ratio covenant once the Availability Block Period concludes.
- Assess the impact of the manufacturing transfer process on working capital requirements and liquidity.
- Confirm the identity of all material direct and indirect domestic subsidiaries acting as Guarantors beyond RITA Medical Systems, LLC.